SXTCChina SXT Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of China SXT Pharmaceuticals, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SXTCThis | $2M#2 | — | 0.1x#1 | 2.0x#2 | -34.6%#2 | -87.8%#2 | -625.9%#3 | -20.9%#2 | -281.4%#2 | — | -100.0%#3 | — |
| SMNR | — | — | — | — | — | -3320.4%#4 | — | — | — | — | — | — |
| SMNRW | — | — | — | — | — | -3320.4%#4 | — | — | — | — | — | — |
| SNY | $51.9B#1 | — | — | — | — | — | — | — | — | — | -10.8%#1 | — |
| SPRC | $2M#3 | — | — | 1.3x#1 | -54.6%#3 | -22.7%#1 | -560.2%#2 | — | — | — | -88.3%#2 | — |
| SVA | — | — | — | — | 6.8%#1 | -589.1%#3 | -127.0%#1 | -4.5%#1 | -11.0%#1 | 3#1 | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice